Pyxis Oncology Future Growth
Future criteria checks 1/6
Pyxis Oncology's earnings are forecast to decline at 23.9% per annum while its annual revenue is expected to grow at 16.7% per year. EPS is expected to grow by 0.08% per annum.
Key information
-23.9%
Earnings growth rate
0.08%
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | 16.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Sep 2024 |
Recent future growth updates
Recent updates
Moment Of Truth Approaches For Pyxis Oncology
Sep 13Pyxis Oncology: Promising Research Amid Cash Constraints
Jun 10Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Mar 28Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Jan 18Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
Feb 18
Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation
Sep 01Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06
Aug 15We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely
Apr 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5 | -109 | -111 | -93 | 5 |
| 12/31/2025 | N/A | -86 | -94 | -64 | 5 |
| 12/31/2024 | 13 | -62 | -70 | -39 | 5 |
| 6/30/2024 | 16 | -59 | -57 | -57 | N/A |
| 3/31/2024 | 16 | -58 | -67 | -65 | N/A |
| 12/31/2023 | N/A | -74 | -77 | -71 | N/A |
| 9/30/2023 | N/A | -94 | -81 | -73 | N/A |
| 6/30/2023 | N/A | -99 | -89 | -76 | N/A |
| 3/31/2023 | N/A | -109 | -99 | -88 | N/A |
| 12/31/2022 | N/A | -121 | -96 | -89 | N/A |
| 9/30/2022 | N/A | -101 | -89 | -84 | N/A |
| 6/30/2022 | N/A | -88 | -71 | -71 | N/A |
| 3/31/2022 | N/A | -71 | -45 | -44 | N/A |
| 12/31/2021 | N/A | -76 | -36 | -35 | N/A |
| 9/30/2021 | N/A | -64 | -27 | -26 | N/A |
| 6/30/2021 | N/A | -53 | -22 | -22 | N/A |
| 3/31/2021 | N/A | -47 | -28 | -27 | N/A |
| 12/31/2020 | N/A | -13 | -12 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PYXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PYXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PYXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PYXS's revenue (16.7% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: PYXS's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PYXS's Return on Equity is forecast to be high in 3 years time